RadNet to acquire iCAD for ~$103M all-stock; ~98% premium

RadNet, Inc.

All-stock acquisition of iCAD for ~$103M (0.0677 RDNT shares per ICAD share); ~98% premium to ICAD's April 14 close.
Expected close in Q2 or Q3 2025, subject to iCAD stockholder approval and customary conditions.
Combines RadNet's DeepHealth with iCAD's ProFound Breast Health Suite; iCAD has 1,500+ provider locations across 50+ countries.
RadNet will host conference call April 16 at 10:30 AM ET to discuss transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.